Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Access number
6%
Acute Lymphoblastic Leukemia
52%
Acute Lymphoblastic Leukemia Cells
10%
Antibody-dependent Cellular Phagocytosis
6%
Ara-C
6%
Autophagy Inhibition
6%
Azacitidine
6%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
6%
B-cell Precursors
7%
BCL11B
6%
BCP-ALL
64%
BCR-ABL1
6%
BCR/ABL Fusion Gene
6%
Biobanking
6%
Biological Characteristics
6%
Bone Marrow
7%
Bone Marrow-derived
6%
Bosutinib
6%
Central Nervous System Involvement
6%
Childhood Acute Lymphoblastic Leukemia
7%
Childhood B-ALL
6%
Childhood B-cell Acute Lymphoblastic Leukemia
7%
Chromosomal Instability
6%
Chromosome 21
13%
Chronic Myeloid Leukemia
6%
Clinical Activity
6%
Clinical Characteristics
7%
Common Region
6%
Conventional Diagnostic Methods
6%
Copy number
6%
Cyclin C
6%
Cytarabine
6%
Disease Progression
6%
Down Syndrome
19%
DUX4
7%
Effective Compounds
6%
EGFR-TKI Resistance
6%
Enhancer Hijacking
6%
ETV6-RUNX1
28%
Event-free Survival
11%
Fusion Gene
6%
Gene Deletion
6%
Genetic Subtypes
7%
Genomic Deletion
6%
Hematopoietic Stem Cell Transplantation
6%
High Hyperdiploid
6%
High Risk
7%
Ibrutinib
6%
IGH Rearrangement
6%
IKZF1 Deletion
21%
IKZF1 Gene Deletion
6%
Improved Outcomes
10%
Interferon-beta (IFN-β)
6%
Interleukin-7 Receptor
6%
Intolerant
6%
Intrachromosomal Amplification of Chromosome 21 (iAMP21)
18%
Kinase Domain mutations
6%
Leukemia
20%
Leukemia Patients
18%
Leukemic Cells
12%
Lymphoblastic Lymphoma
6%
Matched Cohort Study
6%
Mesenchymal Stroma
6%
Mesenchymal Stromal Cells
7%
Minimal Residual Disease
22%
Modified Delphi Method
6%
Molecular Diagnostics
6%
Multilineage
6%
Mutational Landscape
6%
New Agents
6%
Noninfectious Complications
6%
Overall Survival
6%
PAX5
9%
Pediatric
12%
Pediatric B-cell Acute Lymphoblastic Leukemia
6%
Pediatric Patients
9%
Poor Outcome
9%
Primary B Cells
6%
Prognostic Effect
6%
Real-world Experience
6%
Receptor Antagonist
6%
Relapsed/refractory Acute Lymphoblastic Leukemia
6%
Relapsed/refractory Acute Myeloid Leukemia
6%
RNA Sequencing (RNA-seq)
11%
Secondary Lesions
6%
Signal Transduction Inhibitors
7%
SNP Array
5%
Somatic Chromosome
6%
STAP1
6%
Stem Cell Leukemia
6%
Stress Response
6%
Targeted Therapy
9%
Targeted Treatment
6%
TCF3-PBX1
7%
Therapeutic Target
7%
Transcriptional Landscape
6%
Treatment Options
9%
Treatment Protocol
6%
Venetoclax
6%
Xenograft
6%
Biochemistry, Genetics and Molecular Biology
Adolescence
10%
Aurora B Kinase
6%
B Cell
100%
B-Cell Receptor
6%
BCL11B
6%
Blood Plasma
6%
Carcinogenesis
9%
CD22
7%
CDKN2B
6%
Cell Maturation
6%
Cell Viability
6%
Chromosome
13%
Chromosome 21
27%
Chromosome Instability
7%
Condensin
6%
Cryopreservation
6%
Cyclin C
6%
Cyclin Dependent Kinase Inhibitor 2A
9%
Cytarabine
6%
Cytogenetics
12%
DNA Methylation
6%
Down Syndrome
8%
Drug Resistance
6%
DUX4
7%
Enhancer Region
7%
ETV6
23%
Event Free Survival
7%
Exome Sequencing
5%
Fluorescence in Situ Hybridization
5%
Gene Deletion
6%
Genetics
13%
Group Trial
6%
High Risk Population
18%
IKZF1
30%
Janus Kinase
7%
Kinase
13%
MicroRNA
6%
Overall Survival
11%
PAX5
10%
Pediatrics
72%
Phosphotransferase
13%
Precursor
80%
Receptor Tyrosine Kinase
5%
RNA Sequence
20%
RUNX1
22%
SH3 Domain
6%
Single-Nucleotide Polymorphism
5%
Spindle Checkpoint
6%
Stem Cell
6%
Survival Rate
7%
Targeted Therapy
6%
Tyrosine Kinase
5%
Tyrosine Kinase Inhibitor
13%
Medicine and Dentistry
Acute B-Cell Lymphoblastic Leukemia
8%
Acute Lymphoblastic Leukemia
66%
Acute Lymphocytic Leukemia
7%
Acute Myeloid Leukemia
7%
Adolescence
8%
Area under the Curve
5%
Azacitidine
6%
B Cell
20%
Bosutinib
6%
Carcinogenesis
6%
Cell Count
5%
Chemotherapy
5%
Childhood Acute Lymphocytic Leukemia
6%
Chromosome 21
6%
Chronic Myelogenous Leukemia
9%
Clinical Trial
6%
Cohort Analysis
6%
Down Syndrome
10%
Event Free Survival
10%
Fusion Gene
7%
Genetics
7%
Germ Cell
11%
Hematological Cancer
7%
Hematopoietic Stem Cell Transplantation
10%
High Risk Population
17%
Ibrutinib
6%
In Vitro
8%
Infectious Complication
8%
Inotuzumab Ozogamicin
6%
KMT2A
6%
Leukemia
5%
Leukemia in Children
6%
Leukocyte
5%
Long-Term Outcome
8%
Malignant Neoplasm
13%
Minimal Residual Disease
40%
Myeloid Leukemia
6%
Overall Survival
15%
Pediatric Cancer
6%
Pediatrics
46%
Pediatrics Patient
16%
Personalized Medicine
9%
Precision Oncology
6%
Precursor
14%
Retrospective Cohort Study
6%
Risk Stratification
10%
Somatics
9%
Targeted Therapy
9%
Treatment Option
10%
Tumor
6%
Tyrosine-Kinase Inhibitor
9%
Venetoclax
6%